Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis-Reference-Cited by-同舟云学术

Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis

Published:2021-12-31 Issue:4 Volume:56 Page:266-278
ISSN:2287-979X
Container-title:BLOOD RESEARCH
language:en
Short-container-title:Blood Res

Author:

Hur Joon Young¹,Yoon Sang Eun²,Kim Darae³,Choi Jin-oh³,Min Ju-Hong⁴,Kim Byung Jun⁴,Kim Jung Sun⁵,Lee Jung Eun⁶,Choi Joon Young⁷,Jeon Eun-Seok³,Kim Seok Jin²,Kim Kihyun²

Affiliation:

1. Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea

2. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

3. Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

4. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

5. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

6. Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

7. Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://pdf.medrang.co.kr/BR/2021/056/BR056-04-266.pdf

Reference30 articles.

1. Molecular Mechanisms of Amyloidosis

2. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

3. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

4. Duhamel S, Mohty D, Magne J, et al. Incidence and prevalence of light chain amyloidosis: a population-based study. Blood (ASH Annual Meeting Abstracts) 2017;130(Suppl):5577.

5. Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies;F1000Research;2023-02-20